This company listing is no longer active
Nuvo Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Key information
-26.5%
Earnings growth rate
-26.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 26.3% |
| Return on equity | 178.8% |
| Net Margin | 20.9% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Nuvo Pharmaceuticals (TSE:MRV) Has A Somewhat Strained Balance Sheet
Aug 17
Is Nuvo Pharmaceuticals (TSE:MRV) Using Too Much Debt?
Sep 01Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year
May 11These 4 Measures Indicate That Nuvo Pharmaceuticals (TSE:MRV) Is Using Debt Extensively
Feb 22Revenue & Expenses BreakdownBeta
How Nuvo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 72 | 15 | 26 | 0 |
| 30 Jun 22 | 71 | -3 | 25 | 0 |
| 31 Mar 22 | 70 | -12 | 25 | 0 |
| 31 Dec 21 | 69 | -32 | 24 | 0 |
| 30 Sep 21 | 68 | -24 | 24 | 0 |
| 30 Jun 21 | 68 | -9 | 23 | 0 |
| 31 Mar 21 | 64 | -20 | 23 | 0 |
| 31 Dec 20 | 74 | -4 | 23 | 0 |
| 30 Sep 20 | 76 | -7 | 22 | 0 |
| 30 Jun 20 | 78 | 0 | 0 | 0 |
| 31 Mar 20 | 79 | 9 | 26 | 0 |
| 31 Dec 19 | 70 | 3 | 28 | 0 |
| 30 Sep 19 | 55 | -1 | 21 | 0 |
| 30 Jun 19 | 41 | -8 | 44 | 0 |
| 31 Mar 19 | 30 | -13 | 14 | 0 |
| 31 Dec 18 | 20 | -6 | 9 | 0 |
| 30 Sep 18 | 20 | -2 | 11 | 0 |
| 30 Jun 18 | 18 | 0 | 8 | 0 |
| 31 Mar 18 | 15 | -1 | 8 | 0 |
| 31 Dec 17 | 18 | 2 | 7 | 0 |
| 30 Sep 17 | 19 | 4 | 6 | 0 |
| 30 Jun 17 | 21 | 5 | 6 | 0 |
| 31 Mar 17 | 26 | 8 | 6 | 0 |
| 31 Dec 16 | 27 | 7 | 7 | 0 |
| 30 Sep 16 | 29 | 10 | 6 | 0 |
| 30 Jun 16 | 29 | 11 | 6 | 0 |
| 31 Mar 16 | 24 | 8 | 5 | 0 |
Quality Earnings: MRV has high quality earnings.
Growing Profit Margin: MRV became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRV has become profitable over the past 5 years, growing earnings by -26.5% per year.
Accelerating Growth: MRV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MRV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.3%).
Return on Equity
High ROE: Whilst MRV's Return on Equity (178.77%) is outstanding, this metric is skewed due to their high level of debt.